Diversity-oriented synthesis platform producing a broad library of heteroaromatic scaffolds—including pyrroloindoles, pyridoindoles, dihydropyrroles, and pyrroloquinolines—via cascade ring-closing condensations and Friedel–Crafts-type cyclizations. Enables rapid access to diverse, functionalized scaffolds for drug discovery, agrochemical, and materials research.
This offering is a versatile synthetic chemistry platform that delivers highly functionalized heteroaromatic compounds through diversity-oriented synthesis-inspired methodologies. The approach combines cascade ring-closing condensations—starting from sugars or aldehydes—with Friedel–Crafts-type ring-closing strategies that leverage donor–acceptor cyclopropanes and heteroaryl alpha-alkylidene 1,3-dicarbonyls. Because the routes are highly modular, the platform can generate a wide range of heteroaromatic scaffolds bearing diverse functional groups in a systematic way.
Target compound classes include:
The platform is well suited for partners in pharmaceutical, agrochemical, and specialty chemical sectors who need rapid, modular access to complex heterocyclic scaffolds for lead generation, structure–activity relationship studies, or materials innovation.
Synthetic strategies:
Key features:
The methodology has been demonstrated through the successful synthesis of multiple heteroaromatic compound classes, including pyrroloindoles, pyridoindoles, dihydropyrroles, dihydrofurans, and pyrroloquinolines. The platform is at an early-to-mid stage of development, with core synthetic routes validated in the laboratory. It is positioned for collaborative refinement, library expansion, and application-specific optimization with industry partners.
Georgia Institute of Technology is a large, technology‑focused public research university in Atlanta with a strong applied research culture. Industry engages through the Georgia Tech Research Institute for contract R&D, a Midtown innovation district with co‑located corporate labs, and a statewide manufacturing extension to support scale‑up. A long‑standing partnership with a major academic medical center enables clinical translation, and a large co‑op program delivers a steady talent pipeline. Research is backed by competitive federal funding from NSF, NIH, DOE, DoD, and NASA. Technology commercialization is managed by the Georgia Tech Research Corporation, with dedicated licensing, corporate contracting, and startup support.